Speaker
Sungwon Lim, Ph.D., CEO & Co-Founder, ImpriMed, Inc.
Synopsis
In this presentation, Dr. Sungwon Lim, CEO & Co-Founder shares the latest updates from ImpriMed. The team has found that novel tumor and germline genetic biomarkers can increase the accuracy of AI-based treatment outcome predictions when combined with tumor profiling data from ex vivo drug sensitivity assay and comprehensive multicolor flow cytometry assay. ImpriMed is excited to share the new AI results and discuss how genetic information will be incorporated into the canine precision oncology services to support clinical decision-making.
The speakers also present ImpriMed's flagship product, Personalized Prediction Profile, which includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed's artificial intelligence (AI) models, trained on real-world clinical outcome data, predict which anticancer drugs are most likely to be effective for a particular dog's lymphoma or leukemia based on comprehensive testing of each patient's live cancer cells and other information about the patient.